반응식
[OH:1][C:2]([CH3:35])([CH3:34])[CH2:3][C@@:4]1([C:28]2[CH:33]=[CH:32][CH:31]=[CH:30][CH:29]=2)[O:9][C:8](=[O:10])[N:7]([C@H:11]([C:13]2[CH:18]=[CH:17][C:16](B3OC(C)(C)C(C)(C)O3)=[CH:15][CH:14]=2)[CH3:12])[CH2:6][CH2:5]1.Cl[C:37]1[CH:42]=[C:41]([Cl:43])[N:40]=[N:39][C:38]=1[CH3:44]>>[Cl:43][C:41]1[N:40]=[N:39][C:38]([CH3:44])=[C:37]([C:16]2[CH:15]=[CH:14][C:13]([C@@H:11]([N:7]3[CH2:6][CH2:5][C@:4]([CH2:3][C:2]([OH:1])([CH3:35])[CH3:34])([C:28]4[CH:33]=[CH:32][CH:31]=[CH:30][CH:29]=4)[O:9][C:8]3=[O:10])[CH3:12])=[CH:18][CH:17]=2)[CH:42]=1참가 물질
3
반응물 2
생성물 1
실험 절차
The isomeric title compounds were prepared by reaction of (S)-6-(2-hydroxy-2-methylpropyl)-6-phenyl-3-((S)-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborol-an-2-yl)phenyl)ethyl)-1,3-oxazinan-2-one and 4,6-dichloro-3-methylpyridazine following a procedure analogous to that described in Example 14.
출처 및 근거
- ORD 기록
- ord-540e269aafcf4c0e8ef8cc61adab6c21
- 출처 데이터셋
- uspto-grants-2013_10
- 특허 번호
- US08569292B2
연결된 노트
불러오는 중…